Teva Canada Ranitidine Product Recall (2019-10-17)
- Starting date:
- October 17, 2019
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type I
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-71339
Last updated: 2019-10-18
Summary
-
Product:
A. ACT-Ranitidine 150 mg Tablet;B. ACT-Ranitidine 300 mg Tablet
A. ACT-Ranitidine 150 mg Tablet;
B. ACT-Ranitidine 300 mg Tablet
Reason
Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).
Depth of distribution
Wholesalers, Healthcare Establishments, Retailers
Affected products
A. ACT-Ranitidine 150 mg Tablet
DIN, NPN, DIN-HIM
DIN 02248570
Dosage form
Tablet
Strength
Ranitidine 150 mg
Lot or serial number
K51136, K58444, K50205, K50860, K51114, K51139, K51141, K52964, K58446, K46486, K50593, K51071, K51076, K51144, K51146, K51148, K51150, K51152, K51154, K51164, K52965, K52966, K55591, K50203, K51069, K51132
Companies
- Recalling Firm
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
- Marketing Authorization Holder
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
B. ACT-Ranitidine 300 mg Tablet
DIN, NPN, DIN-HIM
DIN 02248571
Dosage form
Tablet
Strength
Ranitidine 300 mg
Lot or serial number
K50175, K50944, K51170, K51171, K51172, K51173
Companies
- Recalling Firm
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
- Marketing Authorization Holder
-
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA